Kristin Taylor, PhD
Vice President and Head of Clinical Development⟵ Back to Team
Dr. Kristin Taylor, Vice President and Head of Clinical Development, joined Escient Pharmaceuticals in July 2019. From 2014 to 2019, Dr. Taylor was Vice President and Head of Clinical Development at Zafgen, Inc, where she headed up efforts to develop novel therapies targeting complex metabolic diseases including type 2 diabetes, obesity and rare forms of obesity. Prior to that, she was Vice President and Head of Clinical Development at Orexigen Therapeutics, Inc with a leadership role in the successful US and European approval of CONTRAVE for treatment of obesity. She held several positions of increasing responsibility at Amylin Pharmaceuticals, including Senior Director of Medical Research, from 2001 to 2010 with a primary role in development of BYETTA and BYDUREON as well as contributing to the development of other products now approved for marketing. Dr. Taylor has extensive clinical research, scientific affairs and regulatory development experience through all phases of clinical development, including rare disease experience. She holds several patents and is co-author of over 35 publications. She received her PhD in Biochemistry from the Medical College of Pennsylvania before conducting post-doctoral studies in the School of Medicine at University of California, San Diego.